Karotid Endarterektomi geçiren hastalarda kontrolsüz diyabetin statin kullanan ve kullanmayan hastalarda LDL seviyelerine etkisi
Abstract
Amaç: Çalışmanın amacı Karotid endarterektomi geçiren hastalarda kontrolsüz diyabetes mellitusun DM uzun süreli statin kullanan ve kullanmayan hastalarda Düşük Yoğunluklu Lipoprotein LDL seviyelerine etkisini araştırmaktı.Gereç ve yöntem: Ateroskleroz nedeniyle karotid endarterektomi geçiren 40 hastanın ameliyat öncesi LDL seviyeleri retrospektif olarak analiz edildi. Tüm hastalar en az 1 yıldır statin kullanıyordu. HbA1C seviyelerinin % 6,4’den fazla olması kontrolsüz DM kriteri kabul edildi D+ . Diğer hastalar diyabet olmayan gruplara alındı D- . Grup 1: D+ statin kullanan n=9 , grup 2: D- statin kullanan n=10 , grup 3: D+ statin kullanmayan n=8 , grup 4: D- statin kullanmayan n=13 hastalardan oluştu. İstatistiksel değerlendirme için Kruskal-Wallis ve Mann-Whitney testleri kullanıldı. p
Keywords
References
- IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract 2015;109:461-5.
- Whayne TF Jr. Atherosclerosis: current status of prevention and treatment. Int J Angiol 2011;20:213-22.
- Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin 2014;32:439-55.
- Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 2005;150:859-70.
- Maki KC, Dicklin MR, Baum SJ. Statins and diabetes. Cardiol Clin 2015;33:233-43.
- Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Prote- ction Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
- Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowe- ring of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
- Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matt- hews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
- Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpu- salo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
- Eeg-Olofsson K, Gudbjörnsdottir S, Eliasson B, Zethelius B, Cederholm J; NDR. The triglycerides-to-HDL-cholesterol ra- tio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Di- abetes Register (NDR). Diabetes Res Clin Pract 2014;106:136- 44.
- Kei A, Rizos EC, Elisaf M. Statin use in prediabetic patients: rationale and results to date. Ther Adv Chronic Dis 2015;6:246- 51.
- Naples M, Fredico LM, Xu E, Nelken J, Adeli K. Effect of ro- suvastatin on insülin sensivity in an animal model of insülin resistance: evidence of statin-induced hepatic insülin sensitiza- tion. Atherosclerosis 2008;198:94-103.
Abstract
Introduction: This study aims to assess the effects of uncontrolled diabetes mellitus DM on LDL levels of atherosclerotic patients on long term statins and patients not on statins.Material and Methods: LDL levels of 40 patients undergoing carotid endarterectomy due to atherosclerosis were retrospectively analyzed. All statin users were on statins for >1yr. Patients with HbA1C levels of >6.4% were considered as uncontrolled DM D+ . All other patients were non diabetics D- . Group1: D+, statin user n=9 , group 2: D- statin user n=10 , group 3: D+ non statin user n=8 , and group 4: D- non statin user n=13 . LDL levels are given as mg/dl, Kruskal-Wallis and Mann-Whitney tests were used for statistics. p0.05 . Conclusions: Results of this study suggest that atherosclerotic patients with uncontrolled diabetes who are either on or off statin therapy have higher LDL results compared to non-diabetic atherosclerotic patients. Further multicenter studies with higher number of patients with proven atherosclerosis are needed
Keywords
References
- IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract 2015;109:461-5.
- Whayne TF Jr. Atherosclerosis: current status of prevention and treatment. Int J Angiol 2011;20:213-22.
- Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin 2014;32:439-55.
- Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 2005;150:859-70.
- Maki KC, Dicklin MR, Baum SJ. Statins and diabetes. Cardiol Clin 2015;33:233-43.
- Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Prote- ction Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
- Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowe- ring of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
- Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matt- hews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
- Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpu- salo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
- Eeg-Olofsson K, Gudbjörnsdottir S, Eliasson B, Zethelius B, Cederholm J; NDR. The triglycerides-to-HDL-cholesterol ra- tio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Di- abetes Register (NDR). Diabetes Res Clin Pract 2014;106:136- 44.
- Kei A, Rizos EC, Elisaf M. Statin use in prediabetic patients: rationale and results to date. Ther Adv Chronic Dis 2015;6:246- 51.
- Naples M, Fredico LM, Xu E, Nelken J, Adeli K. Effect of ro- suvastatin on insülin sensivity in an animal model of insülin resistance: evidence of statin-induced hepatic insülin sensitiza- tion. Atherosclerosis 2008;198:94-103.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Original Article |
| Authors | |
| Publication Date | June 1, 2016 |
| Published in Issue | Year 2016 Volume: 26 Issue: 2 |
The Journal of General Medicine is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC).